Aspirin and Preeclampsia

Launched by UNIVERSITY OF CHICAGO · Jul 18, 2020

Keywords

ClinConnect Summary

This clinical trial, titled "Aspirin and Preeclampsia," is exploring whether taking aspirin can help women who have preeclampsia after giving birth. Preeclampsia is a condition that can cause high blood pressure and other health issues during pregnancy. Researchers believe that a substance called Activin A, which is found in higher levels in women with preeclampsia, could be reduced by taking aspirin, potentially improving heart function in these patients.

To participate, women must be between 18 and 45 years old, have been diagnosed with preeclampsia, and be preparing to deliver a single baby. Unfortunately, women in labor or those with certain health conditions, such as heart or kidney problems, won't be eligible. If you join the study, you'll receive either aspirin or a placebo (a non-active pill) without knowing which one you got, allowing researchers to see if aspirin makes a difference. This trial is currently recruiting participants, and your involvement could help improve care for future mothers experiencing this condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Pregnant Adults between 18 and 45 years of age
• • 2. Diagnosed with preeclampsia
• • 3. Presenting for delivery with a singleton gestation.
• Exclusion Criteria:
• • 1. We will exclude patients in labor
• • 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
• • 3. Plan to deliver outside of the participating site
• • 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
• • 5. Aspirin allergy
• • 6. Clear indication for aspirin therapy or contraindication to aspirin therapy
• • 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
• • 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
• • 9. Those who cannot provide consent